This commercial-stage biotechnology company developing next-generation, targeted antibody drug conjugates is aiming to achieve double-digit year-over-year revenue growth for its lead drug.
The company we are profiling today is ADC Therapeutics SA (ADCT) and the drug in focus is Zynlonta.
Zynlonta, a CD19-directed antibody and alkylating agent conjugate, received FDA approval for the treatment of adult patients with relapsed or refractory large B-cell lymphoma in April 2021.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.